학술논문

Risk factors of rejection after penetrating keratoplasty: a retrospective monocentric study.
Document Type
Article
Source
Graefe's Archive of Clinical & Experimental Ophthalmology. Nov2022, Vol. 260 Issue 11, p3627-3638. 12p.
Subject
*CORNEAL transplantation
*CORNEA surgery
*GRAFT rejection
*GLAUCOMA
*DISEASE risk factors
*GRAFT survival
*KERATOCONUS
*PENETRATING wounds
Language
ISSN
0721-832X
Abstract
Purpose: To assess risk factors of rejection after penetrating keratoplasty (PKP). Methods: This retrospective monocentric study assessed risk factors for rejection in patients who underwent PKP at Montpellier University Hospital between June 2005 and September 2018. Graft and donor data were obtained from our tissue bank in Montpellier. Clinical data of recipients were recorded from medical files. Survival was estimated by the Kaplan-Meir method. Potential risk factors of rejection were assessed by multivariate Cox proportional hazards analysis, estimating hazard ratios (HR) and 95% confidence intervals (CI). Results: Among the 316 consecutive patients (59% male, mean SD] age 52 [17]), 360 eyes underwent PKP. Indications for PKP were bullous keratopathy (27%), infectious keratitis (20%), and keratoconus (15%). The median follow-up was 44 months (IQR 22–73). The overall graft survival and irreversible rejection rate at 5 years were 70% and 29%, respectively. Factors associated with risk of rejection were prior indication for graft rejection (SHR [CI 95%] = 7.8 [2.6–23.1]), trauma (SHR [CI 95%] = 3.6 [1.1–11.7]), and infectious keratitis (SHR [CI 95%] = 2.7 [1.2–11.1]), history of corneal neovascularization (SHR [CI 95%] = 2.1 [1.2–3.8]), hypertonia (SHR [CI 95%] = 2.8 [1.8–4.3]), and mixed sex matching (SHR [CI 95%] = 2.0 [1.01–4.0]). Conclusion: The significant risk factors of graft rejection after PKP found in this study agree with those from major international cohorts: prior indication for graft rejection, history of neovascularization and high intraocular pressure. Sex matching donor-recipient is a most recent parameter in the literature confirmed by the present analysis. Trial registration: ClinicalTrials.gov Identifier: NCT04791696. [ABSTRACT FROM AUTHOR]